Lipid profile after switching from TDF (tenofovir disoproxil)-containing to TAF (tenofovir alafenamide)-containing regimen in virologically suppressed people living with HIV

Michał Łomiak

Students' Science Society of the Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Poland

https://orcid.org/0000-0001-9109-8776

Corresponding author: lomiak.m@gmail.com

Zofia Gajek

Students' Science Society of the Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Poland

iD —

Jan Stępnicki

Students' Science Society of the Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Poland

iD —

Agnieszka Lembas

Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Poland; Hospital for Infectious Diseases in Warsaw, Poland

iD —

Tomasz Mikuła

Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Poland; Hospital for Infectious Diseases in Warsaw, Poland

iD —

Alicja Wiercińska-Drapało

Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Poland; Hospital for Infectious Diseases in Warsaw, Poland

iD —

ABSTRACT

Background. Tenofovir disoproxil fumarate (TDF) or its prodrug tenofovir alafenamide fumarate (TAF) are currently being recommended in treatment of HIV infection. Distinct pharmacological properties of these two forms of a this drug make TAF treatment less nephrotoxic and lead to better impact on bone density. Nevertheless, there is a rising concern about possible metabolic adverse effects of TAF. The purpose of this study was to evaluate the effects on the lipid profile among ART (antiretroviral therapy)-experienced patients switching from TDF-containing to TAF-containing regimen in the first year after the switch.

Methods. Demographic and clinical data of HIV-positive ART-experienced patients treated in infectious diseases department was retrospectively collected. Changes of lipid profile with regards to baseline BMI, age and time of ART duration were analyzed.

Results. In the group of 36 patients there was a significant increase in total cholesterol levels (+18.43 mg/dl, SD = 23.86 mg/dl, p < 0.0001) and LDL levels (+13.75 mg/dl SD = 23.05 mg/dl, p = 0.001) in first 12 months after switching from TDF-containing to TAF-containing regimen. There were no statistically significant changes in both HDL and TG levels observed. Analysis of total cholesterol and LDL levels in certain subpopulations revealed a significant increase within first year after the switch in patients younger than 40 years old and in those whose BMI was within normal range.

Conclusions. Presented data suggests that switching from TDF to TAF in ART-experienced patients may be associated with worsening lipid parameters. Early detection and management of dyslipidemias among HIV-positive patients are needed.

Introduction

The main aims of antiretroviral therapy (ART) in HIV-positive patients are undetectable viral load, reduction of transmission of the virus, restoration of the immune system and decrease of AIDS-associated mortality [1]. The availability of effective and safe antiretroviral drugs led to an improvement in life expectancy among people living with HIV (PLWH) to the point where it is close to the non-infected population [2, 3]. Nevertheless, in the era of worldwide access to long-term treatment of HIV infection, currently, the main causes of mortality are non-AIDS-associated comorbidities such as metabolic and cardiovascular diseases [4]. The incidence of ischemic heart disease, arterial hypertension, diabetes mellitus, or dyslipidemia is significantly higher among PLWH compared to healthy individuals [5]. The pathophysiology processes leading to these observations are complex and involve endothelial dysfunction associated with the chronic inflammatory state despite suppression of virus replication, dysregulation of the immune system, high incidence of traditional risk factors (e.g. smoking), or side effects of drugs included in ART [6].

Tenofovir alafenamide (TAF) and tenofovir disoproxil (TDF) are two forms of tenofovir that are currently recommended in the treatment of HIV infection [7]. TAF has been shown to display non-inferior antiviral properties compared with TDF in both HIV infection treatment and pre-exposure prophylaxis [8, 9]. TAF is the next-generation tenofovir prodrug with a distinct pharmacological profile. The active metabolite of these two drugs (tenofovir diphosphate) can achieve even 25-times higher concentrations in peripheral mononuclear blood cells following consumption of TAF compared with TDF [10]. Pharmacological studies have shown that tenofovir undergoes active uptake by white blood cells when its precursor is TAF [11, 12]. Hence it is possible to significantly decrease the dosage of TAF compared with TDF, which subsequently leads to a better safety profile – lower nephrotoxicity risk and lesser damage to bone structural integrity [13].

Nevertheless, recent reports bring up a concern about the substitution of TDF with TAF in ART due to a possible increase in cardiovascular risk after the switch of these drugs [14]. In this single-center retrospective study, we aimed to evaluate whether switching treatment from a TDF-containing regimen to a TAF-containing regimen is associated with worsening of serum lipids parameters in the ART-experienced cohort.

Patients and methods

We analyzed data gathered in routine care patients' charts admitted to our department. The research included patients that met the general inclusion criteria as follows: confirmed HIV infection, age over 18 years, no active neoplastic disease, switching from TDF-based regimen to TAF-based regimen, and confirmed efficacy of virologic suppression on TAF-based regimen (<200 copies/mL of HIV RNA after at least 6 months from treatment initiation). Patients were treated with various antiretroviral regimens that included TDF, such as TDF/emtricitabine/lopinavir/ritonavir, TDF/emtricitabine/darunavir/

ritonavir and TDF/emtricitabine/efavirenz. They were later switched to TAF-based regimens: TAF/elvitegravir/emtricitabine/cobicistat or TAF/emtricitabine/rilpivirine.

Lipid concentration measures were taken including total cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL) concentration, and triglycerides (TG). These measures were taken firstly at the beginning of TAF-containing ART (at the moment of the switch from TDF-containing ART) and then 12 months after switching from TDF-containing ART. Additional information that was collected included duration of HIV infection, duration of ART, number of previous treatment schemes, route of infection, HIV RNA viral load and CD4+ count at the moment of infection diagnosis, CD4+ at the time of switching of ART regimens, co-infection with other sexually transmitted diseases (STDs). Optimal values of lipid parameters were distinguished according to Adult Treatment Panel Guidelines III and were < 200 mg/dl for total cholesterol, <100 mg/dl for LDL, <150 mg/dl for TG and > 40 mg for HDL in plasma serum [6].

Paired t-student tests were applied to compare changes in concentration of described lipid parameters with the use of GraphPad Prism 8.4.3 software. The statistical significance of the results was regarded as a p-value < 0.05.

Results

Study population
A total of 106 patient history charts were analyzed. Eventually, 36 patients met the inclusion criteria. All the patients in the study group were Caucasians and predominantly male. The median duration of ART among patients was nine years and more than half of them have changed their ART regimen more than two times. Importantly, we observed a high prevalence of co-infection with other sexually transmitted diseases in the study group. More than half of patients declared the most possible transmission by sexual contact and belonged to the group described as "men having sex with men". All baseline characteristics of the study group have been presented in **Table 1** (see next page).

Lipids parameters changes in the study population
Our data indicates a high frequency of patients whose lipid parameters were not optimal at the beginning of the study which is at the time of the switch from TDF-containing to TAF-containing regimen. Twelve months after switching, the number of patients with different types of dyslipidemia raised from 6 to 10 for total cholesterol levels, 13 to 20 for LDL levels, 12 to 17 for TG levels and finally, 8 to 11 for HDL levels (**Figure 1**). Mean values of lipid parameters at the time of switching regimens were 162.5 mg/dl (SD = 36.04 mg/dl) for total cholesterol, 91.48 mg/dl (SD = 29.14 mg/dl) for LDL, 48.17 mg/dl (SD = 15.13 mg/dl) for HDL and 138.8 mg/dl (SD = 68.65 mg/dl) for TG. We observed a significant increase in total cholesterol levels (+18.43 mg/dl, SD = 23.86 mg/dl, p < 0.0001) and LDL levels (+13.75 mg/dl, SD = 23.05 mg/dl, p = 0.001) in first 12 months after switching from TDF-containing to TAF-containing regimen (**Figure 2**). Changes in both HDL and TG levels were

Figure 1. Number of patients with optimal and not optimal lipid parameters at the time of the switch of ART regimen and 12 months after the switch.

Table 1. Descriptive baseline characteristics for the study population.

	Study group (n = 36)
Age in years, median (IQR)	42 (13.25)
Male, n (%)	32 (87.50)
Female, n (%)	4 (12.50)
Caucasian, n (%)	36 (100.0)
Height (cm), median (IQR)	178 (6.50)
Weight at the time of switching TDF to TAF (kg), median (IQR)	75 (10.75)
BMI at the time of switching TDF to TAF in kg/m^2, median (IQR)	24.20 (3.90)
Duration of HIV infection in years, median (IQR)	9 (5.00)
Duration of HIV treatment in years, median (IQR)	9 (4.50)
Number of patients that in the past had 2 different ART regimens before switching to a TAF-based regimen, n (%)	14 (38.90)
Number of patients that in the past had 3 or more different ART regimens before switching to a TAF-based regimen, n (%)	22 (61.10)
Declared route of infection	
– MSM, n (%)	18 (50.0)
– HET, n (%)	12 (33.30)
– IDU, n (%)	2 (5.60)
– no information, n (%)	4 (11.10)
– Co-infection with other STDs (HCV, HBV, syphilis), n (%)	16 (44.40)
Viral load at the time of HIV infection diagnosis (HIV RNA copies/mL), median (IQR)	100892 (368443.00)
CD4+ count at the time of HIV infection diagnosis, median (IQR)	273(183.75)
CD4+ count at the time of the switch to TAF-based regimen, median (IQR)	585 (346.00)
Cardiovascular comorbidities	
– Hypertension (%)	8 (22.2)
– Heart failure (%)	0 (0)
– Coronary artery disease (%)	0 (0)
– Heart failure (%)	0 (0)
– Previous myocardial infarction (%)	0 (0)
– Previous stroke (%)	0 (0)
– Diabetes mellitus (%)	0 (0)
Other drugs used	
– Statins (%)	9 (25)
– Fibrate (%)	2 (5.6)
– Acetylosalicylic acid (%)	1 (2.8)
– Vitamin K antagonists/novel oral anticoagulants (%)	0 (0)
– Beta-blocker (%)	2 (5.6)
– Calcium channels blocker (%)	3 (8.3)
– ACE-inhibitor/sartan (%)	8 (22.2)
– Diuretics (%)	2 (5.6)
– Hypoglycemic drugs (%)	0 (0)

Legend: HET – heterosexual transmission; MSM – transmission between men having sex with men; IDU – transmission through intravenous drug use; IQR – interquartile range.

not statistically significant. During the study period, which is first year of TAF treatment, there were eight patients treated with statin, one patient treated with fibrate and one on dual hypolipidemic treatment with statin and fibrate. No changes in type of hypolipemic drug, its dosage or proportion of patients treated with hypolipemic drugs were observed during study period.

Next, we investigated whether total cholesterol and LDL levels in individual subgroups of the study group changes regarding patients' baseline BMI, age, and ART duration. It was shown that a significant increase in total cholesterol and LDL serum levels after switching to a TAF-containing regimen occurred in patients with a BMI below 25 and patients younger than 40 years old. In both

Figure 2. Mean lipid parameter levels at the time of the switch from TDF-containing to TAF-containing regimen and after 12 months of treatment with TAF-containing regimen.

Table 2. Total cholesterol and LDL changes in the study group according to BMI, age, and ART duration.

	Number of patients	Total cholesterol		LDL	
		Mean change (SD) mg/dl	p-value	Mean change (SD) mg/dl	p-value
BMI value					
<25	25	21.27 (23.59)	0.002	18.17 (23.59)	0.0008
≥25	11	11.98 (23.98)	0.13	3.8 (19.34)	0.5125
Age					
<40 years old	22	20.88 (17.79)	<0.0001	12.76 (16.24)	0.0014
≥40 years old	14	14.3 (31.32)	0.11	15.08 (31.71)	0.09
ART duration					
<10 years	21	19.72 (27.45)	0.004	13.53 (24.36)	0.0211
≥10 years	15	17.01 (18.17)	0.003	13.92 (21.66)	0.0233

subgroups of patients with ART duration of less than or more than 10 years, we reported a significant increase in total cholesterol and LDL serum levels (**Table 2**)

Discussion

In the present study describing the effects of a switch from TDF-based to TAF-based ART regimen in a real-world setting, we have observed a significant worsening of lipid parameters among ART-experienced patients in the first year after the switch. The most prominent, unfavorable changes in lipid parameters were seen in total cholesterol (+18.4 mg/dl) and LDL (+13.72 mg/dl) levels, while there was no significant increase in HDL and TG levels during the study period. Surprisingly, the analysis showed that effects of regimen change leading to statistically significant worsening of total cholesterol and LDL levels occur mostly among younger patients (below 40 years

old) and patients with normal baseline BMI. Study group included in this study consisted of relatively young patients (median age 42), which explains low rate of cardiovascular comorbidities that was observed. Nevertheless, we have observed a high rate of patients without optimal lipid parameters after one year after the change of ART regimen, as well as just before the switch. These observations bring concern about the non-adequate treatment of lipid disorders or underdiagnosing of dyslipidemias among PLWH. There is an urgent and unfulfilled need for an active search for metabolic disorders in that group of patients. Presented data may help to identify groups of patients who are at a higher risk of developing metabolic disturbances after switching from TDF to TAF and among whom additional surveillance on lipid parameters should be performed.

Since the beginning of the global HIV/AIDS pandemic, which has already resulted in nearly 40 million deaths, the possibilities of treatment for patients infected with HIV have widened greatly.

Currently, long-term treatment with safe anti-retroviral drugs provides the suppression of HIV replication and reduces its transmission. Regarding the high efficacy of that treatment, prevention of ART-related adverse effects and maintenance of adherence are the main pitfalls that need to be faced by medical professionals. In the era of widely available ART, the population of HIV-positive patients is aging which leads to an overlap of HIV-associated as well as age-associated health problems including neurodegenerative disorders, malignancies, and cardiovascular events [15].

Compared to uninfected patients, PLWH were proven to have a 1.5–2 times higher risk of cardiovascular events including myocardial infarction, ischemic stroke, heart failure or venous thrombosis [16]. It is the consequence of the interplay of traditional risk factors (such as the high rate of cigarette smokers), chronic viral infection triggering inflammation, and adverse metabolic effects of ART components [, 18]. Chronic inflammation, which is caused by the hyperactivity of T cells, macrophages, monocytes and dendritic cells producing excess cytokines causes damage to the endothelium [19]. That exact process results in the formation of necrotic tissue with a mass of foam cells containing LDL known as atherosclerotic plaques – a morphological manifestation of atherosclerotic disease. High levels of LDL and non-HDL cholesterol were associated with an increase in cardiovascular mortality in the general population which should be considered when choosing ART components [20]. The worsening of lipids profile after switching ART components brings concerns about the potential atherogenic effect of certain drugs. This phenomenon is especially interesting when TDF is replaced with its newer generic formulation TAF. Available data from research papers regarding TAF-associated dyslipidemia after the switch from TDF-containing ART were gathered in **Supplementary Table 1**.

It has been shown that treatment with TAF/FTC/EVG/c compared to TDF/FTC/EVG/c results in a higher increase in total cholesterol, LDL, HDL, and TG in the period of 48 weeks among ART-experienced patients [21]. Also, in phase 3 clinical trial, evaluating the safety of switching from RPV/FTC/TDF to RPV/FTC/TAF, researchers reported a significant increase in total cholesterol, LDL, HDL, and TG after 96 weeks among patients who switched from TDF to TAF compared to those who remained on TDF-containing ART [22]. Similar observations to our results were made by research groups from Finland and Ireland that reported the worsening of lipid parameters after switching from TDF-based to TAF-based ART [23, 24]. The biggest change was observed in total cholesterol and LDL class. While patients' HDL levels increased only slightly, they were still statistically significant. Another TDF-to-TAF switch study showed nearly the same extent of lipid parameter changes in the time observation during the period of 6 months, which may suggest that longer use of TAF in the ART regimen does not lead to more severe dyslipidemia in further months of treatment [25]. This hypothesis is consistent with data obtained by Huhn et. al [26] where patients` dynamics of lipid changes occurred mainly in the first 48 weeks after the ART switch with only minimal changes in the period from 48 to 96 weeks of observation after initiation of HIV infection treatment. It was also shown that worsening of total cholesterol and LDL levels after the switch occurs mostly in patients without baseline hypercholesterolemia [27]. This may explain why, in our group, we observed a significant change in these parameters among patients below 40 years old and with a normal BMI. However, the switch from TDF to TAF in patients with baseline hypercholesterolemia resulted in a significant decrease in LDL/HDL and TC/HDL ratios, which are markers of ischemic heart disease risk [28]. Interestingly, the effect of TAF on lipids by switching from TDF to TAF seems to be reversible when setting the patient back on TDF-containing ART [29]. That confirms reports about the lipid-lowering properties of TDF on all lipid fractions that may be associated with plasma levels of TFV [30]. Although the lipid-lowering effect of TDF seems to be comparable to some statins, it is still unknown whether the changes in lipid parameters in such cases correspond with a reduction of death risk from cardiovascular events in the future as it was proven to be associated with statin use [31]. It should be stressed that the exact mechanism of TDF improving lipid parameters is not clear, but probably involves other actions than only the suppression of HIV replication since this phenomenon was also observed in the treatment of HBV infection [32] and HIV pre-exposure prophylaxis [33].

Supplementary Table 1. Current knowledge about the impact of TAF-based ART regimen after switching from TDF-based regimen on lipid parameters among ART-experienced HIV+ patients.

No. of patients	Time of observation (weeks)	Median or mean change of lipid parameters (mg/dl)				Additional information	Study
		Total cholesterol	LDL	HDL	TG		
110	48 weeks on TDF-based ART; 48 weeks on TAF-based ART	+12.50* (median)	+8.20* (median)	+3.00* (median)	+ 4.00 (median)	– presented changes of lipids parameters are between one year before ART switch and one year after; – 13% increase in ASCVD risk scores after switching to TAF	[14]
included in analysis: for total cholesterol and TG – 385 for HDL and LDL – 70	12	+20.00* (mean)	+10.00* (mean)	+6.00* (mean)	+23.00* (mean)	– results demonstrate a reversible effect on lipids parameters by switching from TDF to TAF and back	[29]
194	24	+ 14.30* (mean)	+ 9.67* (mean)	+1.90* (mean)	+11.50* (mean)	– the use of statins significantly reduced the risk of worsening lipid panel after switching to TAF	[24]
189	48	+29.00* (mean)	+20.90* (mean)	+3.30* (mean)	+28.90* (mean)	– presented changes of lipids parameters occurred in group of patients without any lipid lowering therapy – it was necessary to prescribe almost twice as much lipid lowering drugs in a group of patients on TAF-based ART compared with TDF-based ART	[21]
included in analysis: for total cholesterol – 431 for LDL – 423 for HDL – 426 for TG – 430	12 (median)	+15.00* (mean)	+9.00* (mean)	+5.00* (mean)	+12.00* (median)	– TC, HDL and LDL increased after the switch in patients without HC, while in HC patients there was no significant variations in TC and LDL, but with decrease of TC/HDL and LDL/HDL ratio and increase of HDL	[27]
221	34	+19.00–34.00* (median) depending on other ART agents	+14.00–25.00 (median) depending on other ART agents	+4.00–7.00 (median) depending on other ART agents	+7.00–21.00 (median) depending on other ART agents	– after switching from TDF to TAF, the proportion of patients with LDL above their CV target increased significantly	[39]
347	24	+21.00* (mean)	+14.00* (mean)	+7.00* (mean)	+16.00* (mean)	– despite an increase in total cholesterol, triglycerides and LDL cholesterol after the TDF-to-TAF switch, no difference was found in the LDL:HDL cholesterol ratio, an essential predictor of cardiovascular risk	[25]
490	42	+23.20* (median)	+15.50* (median)	+3.50* (median)	+15.50* (median)	– the increases in lipid concentrations were similar between the participants receiving a non-NRTI, protease inhibitor or INSTI-based ART. The use of a boosting agent (ritonavir or cobicistat) did not affect the observed changes in lipid concentrations.	[23]
148	24	+13.40* (mean)	+7.60* (mean)	+3.80* (mean)	+3.00* (median)	– changes in blood lipids did not determine a significant variation in cardiovascular risk scores after 6 months from switch	[40]
4328	17 (median)	+12.00* (median)	+8.00* (median)	+2.00* (median)	+14.00* (median)	– 59% of patients with an elevated ASCVD risk were not prescribed statins at any point on or after their first lipid panel after switch	[41]
included in analysis: for total cholesterol – 98 for LDL – 95 for HDL – 96 for TG – 98	9 monts-2.5 years	+8.70* (mean)	+1.70 (mean)	+2.90* (mean)	+20.00* (mean)	– -study presents underutility of statins after switching from TDF to TAF	[42]
118	52 weeks	no data	+16.00* (median)	no data	+28.00* (median)	– -TAF-based therapy had a statistically significantly worse effect on lipid parameters than TDF- based therapy	[43]

* statistically significant change
ASCVD – atherosclerotic cardiovascular disease

Both our and other researchers' findings indicate the unfulfilled need for screening for dyslipidemia and assessing the cardiovascular risk of HIV-positive patients treated with ART. A high proportion of patients with dyslipidemia brings concern about the insufficient administration of lipid lowering agents in the HIV-positive population. In recent years, the problem of the so-called, "statin gap" has been addressed in multiple research papers indicating that PLWH are less likely to be treated with statins according to current lipid-lowering treatment recommendations compared with HIV-negative patients [34]. What is more, the intensity of treatment has been reported to be inadequate in the context of choosing the type of statin and its daily dosage [35, 36], which may be the result of physicians' fear of potential drug-drug interactions. The metabolism of some statins and ART drugs includes the influence on cytochrome P450 which results in a higher (but still low) risk of drug toxicity and attenuation of the effect of therapy [37]. Nevertheless, the administration of lipid-lowering therapy should be considered a milestone in the long-term care of HIV-positive patients. Potential interactions with antiretrovirals can be managed by careful selection of the appropriate statin or another drug [38]. Also, other factors that may contribute to non-optimal lipid parameters among patients should be considered, such as non-adherence, suboptimal physician-provider/patient relationships, or overestimation of the effect of diet control.

This study has several limitations that should be stated. Firstly, the sample size was relatively small with no comparator group that would consist of patients continuing TDF-based treatment. The disadvantage of the study is also the inability to gather data about other factors that can influence lipid parameters such as dietary habits or physical activity. Nevertheless, our research provide data from a real-world setting with a comparatively long observation period of one year which is still scarce among currently published articles.

In conclusion, the presented data suggest that it is possible that TAF could worsen the lipids parameters in ART-experienced patients, especially those who are younger than 40 years old and those within the normal BMI range. This effect should be taken into consideration by both clinicians and patients when deciding to include TAF in ART. All PLWH should be informed of the need to monitor their lipid parameters to facilitate their detection and management of dyslipidemia. Prospective studies on the possible mechanisms behind this metabolic phenomenon, including identification of the risk factors of lipid disorders after a switch to a TAF-containing regimen, are required. Professional societies should emphasize the importance of improving the quality of cardiovascular care among PLWH through early detection and proper management of dyslipidemias.

References

1. Davenport MP, Khoury DS, Cromer D, Lewin SR, Kelleher AD, Kent SJ. Functional cure of HIV: the scale of the challenge. Nat Rev Immunol. 2019;19(1):45-54.
2. Marcus JL, Leyden WA, Alexeeff SE, Anderson AN, Hechter RC, Hu H, et al. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016. JAMA Netw Open. 2020;3(6):e207954.
3. Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256-66.
4. Atta MG, De Seigneux S, Lucas GM. Clinical Pharmacology in HIV Therapy. Clin J Am Soc Nephrol. 2019;14(3):435-44.
5. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506-12.
6. Jachymek M, Braksator M, Parczewski M, Peregud-Pogorzelska M, Kaźmierczak J. Cardiovascular disease and HIV infection. HIV & AIDS Review International Journal of HIV-Related Problems. 2021;20(2):85-9.
7. European AIDS Clinical Society Guidelines. October 2021;version 11.0
8. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil

fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606-15.

9. Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239-54.

10. Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449-55.

11. Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49(5):1898-906.

12. Di Perri G. Tenofovir alafenamide (TAF) clinical pharmacology. Infez Med. 2021;29(4):526-9.

13. Di Perri G. Tenofovir alafenamide revisited. Infez Med. 2020;28(4):525-33.

14. Schafer JJ, Sassa KN, O'Connor JR, Shimada A, Keith SW, DeSimone JA. Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide. Open Forum Infect Dis. 2019;6(10):ofz414.

15. So-Armah K, Benjamin LA, Bloomfield GS, Feinstein MJ, Hsue P, Njuguna B, et al. HIV and cardiovascular disease. Lancet HIV. 2020;7(4):e279-e93.

16. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis. Circulation. 2018;138(11):1100-12.

17. Łomiak M, Stępnicki J, Mikuła T, Wiercińska-Drapało A. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group. Int J STD AIDS. 2021;32(6):570-7.

18. Shah S, Hill A. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy. Curr Opin Infect Dis. 2021;34(1):16-24.

19. Ammirati E, Moroni F, Magnoni M, Camici PG. The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol. 2015;179(2):173-87.

20. Abdullah SM, Defina LF, Leonard D, Barlow CE, Radford NB, Willis BL, et al. Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. Circulation. 2018;138(21):2315-25.

21. Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Mena-De-Cea Á, López-Calvo S, et al. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol. 2019;124(4):479-90.

22. Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med. 2018;19(10):724-33.

23. Kauppinen KJ, Kivelä P, Sutinen J. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting. AIDS Patient Care STDS. 2019;33(12):500-6.

24. Lacey A, Savinelli S, Barco EA, Macken A, Cotter AG, Sheehan G, et al. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV. Aids. 2020;34(8):1161-70.

25. Schwarze-Zander C, Piduhn H, Boesecke C, Schlabe S, Stoffel-Wagner B, Wasmuth JC, et al. Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications? HIV Med. 2020;21(6):378-85.

26. Huhn GD, Shamblaw DJ, Baril JG, Hsue PY, Mills BL, Nguyen-Cleary T, et al. Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate. Open Forum Infect Dis. 2020;7(1):ofz472.

27. Taramasso L, Di Biagio A, Riccardi N, Briano F, Di Filippo E, Comi L, et al. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. PLoS One. 2019;14(10):e0223181.

28. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med. 2001;161(22):2685-92.

29. Milinkovic A, Berger F, Arenas-Pinto A, Mauss S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. Aids. 2019;33(15):2387-91.

30. Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(3):403-8.

31. Orkaby AR, Driver JA, Ho YL, Lu B, Costa L, Honerlaw J, et al. Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older. Jama. 2020;324(1):68-78.

32. Lim J, Choi WM, Shim JH, Lee D, Kim KM, Lim YS, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B. Liver international : official jour-

nal of the International Association for the Study of the Liver. 2022;42(7):1517-27.

33. Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, et al. Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clin Infect Dis. 2018;67(3):411-9.

34. Blackman AL, Pandit NS, Pincus KJ. Comparing rates of statin therapy in eligible patients living with HIV versus uninfected patients. HIV Med. 2020;21(3):135-41.

35. Pincus KJ, Blackman AL, Suen SY, Devabhakthuni S, Gale S, Noel ZR, et al. Statin gap in patients living with HIV: assessing dose appropriateness. HIV Med. 2021;22(10):917-23.

36. Aragon KG, Ray G, Conklin J, Stever E, Marquez C, Magallanes A, et al. Underprescribing of statin therapy in people with HIV at risk for atherosclerotic cardiovascular disease. Am J Health Syst Pharm. 2022.

37. Jiménez-Nácher I, Alvarez E, Morello J, Rodriguez-Nóvoa S, de Andrés S, Soriano V. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol. 2011;7(4):457-77.

38. Maggi P, Di Biagio A, Rusconi S, Cicalini S, D'Abbraccio M, d'Ettorre G, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017;17(1):551.

39. Gazzola L, Tagliaferri G, De Bona A, Mondatore D, Borsino C, Bini T, et al. Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance? HIV Med. 2021;22(2):140-5.

40. Squillace N, Ricci E, Menzaghi B, De Socio GV, Passerini S, Martinelli C, et al. The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile. Drug Des Devel Ther. 2020;14:5515-20.

41. Brunet L, Mallon P, Fusco JS, Wohlfeiler MB, Prajapati G, Beyer A, et al. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization. Clin Drug Investig. 2021;41(11):955-65.

42. Plum PE, Maes N, Sauvage AS, Frippiat F, Meuris C, Uurlings F, et al. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC Infect Dis. 2021;21(1):910.

43. Kanda N, Okamoto K, Okumura H, Mieno M, Sakashita K, Sasahara T, et al. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan. HIV Med. 2021;22(6):457-66.